Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志  2016, Vol. 36 Issue (7): 127-133    DOI: 10.13523/j.cb.20160717
讲座     
讲座细胞药物的制备工艺——细胞药物连载之二
王佃亮
中国人民解放军火箭军总医院药学部组织工程与再生医学实验室 北京 100088
The Preparation Technology of Cell Drug
WANG Dian-liang
Tissue Engineering and Regenerative Medicine Laboratory, The General Hospital of The PLA Rocket Force, Beijing 100088, China
 全文: PDF(495 KB)   HTML
摘要:

细胞药物制备的质量直接关系到细胞治疗的效果。由于细胞治疗所用细胞是具有生物学效应的,细胞药物的制备技术和应用方案具有多样性、复杂性和特殊性,不像一般生物药物那样有统一的制作标准。细胞药物的制备过程主要包括供者筛查、供者检测、采集、加工、分离纯化、储存等,以造血干细胞、间充质干细胞、肝细胞及树突状细胞为例对其进行简要介绍。

关键词: 细胞药物肝细胞树突状细胞造血干细胞制备工艺间充质干细胞    
Abstract:

The quality of cell drug preparation is directly related to the curative efficacy of cell therapy. Due to the reason that the cells for cell therapy have biological effects, the preparation technology and application solution for cell drug are of diversity, complexity and particularity, unlike the traditional biological drugs that have a unified production standard. The preparation process of cell drugs mainly include donor screening, donor detection, collection, processing, separation and purification, storage and so on. The preparation technologies of several cell drugs including hematopoietic stem cell, mesenchymal stem cell, hepatic cell and dendritic cell are briefly introduced.

Key words: Hematopoietic stem cell    Mesenchymal stem cell    Dendritic cell    Hepatic cell    Cell drug    Preparation technology
收稿日期: 2016-02-04 出版日期: 2016-07-25
ZTFLH:  Q819  
通讯作者: 王佃亮     E-mail: wangdianliang@sina.com
服务  
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章  

引用本文:

王佃亮. 讲座细胞药物的制备工艺——细胞药物连载之二[J]. 中国生物工程杂志, 2016, 36(7): 127-133.

WANG Dian-liang. The Preparation Technology of Cell Drug. China Biotechnology, 2016, 36(7): 127-133.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20160717        https://manu60.magtech.com.cn/biotech/CN/Y2016/V36/I7/127

[1] Onizuka M,Matsushita H,Machida S,et al.Bacterial pneumonia-induced persistent remission of severe immune thrombocytopenia after allogeneic hematopoietic stem cell transplantation.Intern Med,2016,55(2):179-183.
[2] Sheppard D,Bredeson C,Huebsch L,et al.A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers:results from the Canadian Special Access Program.Bone Marrow Transplant,201449(6):751-755.
[3] Veeraputhiran M,Jain T,Cronin S,et al.Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.J Clin Apher,2014,29(6):293-298.
[4] Tassoni A,Gutteridge A,Barber A C,et al.Molecular mechanisms mediating retinal reactive gliosis following bone marrow mesenchymal stem cell transplantation.Stem Cells,2015,33(10):3006-3016.
[5] Pati S,Muthuraju S,Hadi R A,et al.Neurogenic plasticity of mesenchymal stem cell,an alluring cellular replacement for traumatic brain injury.Curr Stem Cell Res Ther,2016,11(2):149-157.
[6] Aras Y,Sabanci P A,Kabatas S,et al.The effects of adipose tissue-derived mesenchymal stem cell transplantation during the acute and subacute phases following spinal cord Injury.Turk Neurosurg,2016,26(1):127-139.
[7] Whiteley J,Bielecki R,Li M,et al.An expanded population of CD34+ cells from frozen banked umbilical cord blood demonstrate tissue repair mechanisms of mesenchymal stromal cells and circulating angiogenic cells in an ischemic hind limb model.Stem Cell Rev,2014,10(3):338-350.
[8] Badowski M,Muise A,Harris D T.Mixed effects of long-term frozen storage on cord tissue stem cells.Cytotherapy,2014,16(9):1313-1321.
[9] Rodrigues R M,Heymans A,De Boe V,et al.Toxicogenomics-based prediction of acetaminophen-induced liver injury using human hepatic cell systems.Toxicol Lett,2016,240(1):50-59.
[10] Bellwon P,Truisi G L,Bois F Y,et al.Kinetics and dynamics of cyclosporine A in three hepatic cell culture systems.Toxicol In Vitro,2015,30(1 Pt A):62-78.
[11] Wei X C,Yang D D,Han X R,et al.Bioactivity of umbilical cord blood dendritic cells and anti-leukemia effect.Int J Clin Exp Med,2015,8(10):19725-19730.
[12] Yan L,Wu M,Ba N,et al.Efficacy of dendritic cell-cytokine-induced killer immunotherapy plus intensity-modulated radiation therapy in treating elderly patients with esophageal carcinoma.Genet Mol Res,2015,14(1):898-905.

[1] 王宇轩,陈婷,张永亮. MiR-148生物学功能研究进展*[J]. 中国生物工程杂志, 2021, 41(7): 74-80.
[2] 李开秀,司维. 间充质干细胞来源的外泌体治疗炎症性肠病研究进展*[J]. 中国生物工程杂志, 2021, 41(7): 66-73.
[3] 赵久梅,王哲,李学英. 调控软骨形成的信号通路及相关因子在骨髓间充质干细胞骨向分化中的作用*[J]. 中国生物工程杂志, 2021, 41(10): 62-72.
[4] 苑亚坤,刘广洋,刘拥军,谢亚芳,吴昊. 间充质干细胞基础研究与临床转化的中美比较[J]. 中国生物工程杂志, 2020, 40(4): 97-107.
[5] 陈利军,屈晶晶,项春生. 间充质干细胞在2019新型冠状病毒肺炎(COVID-19)中的治疗潜能、临床研究与应用前景*[J]. 中国生物工程杂志, 2020, 40(11): 43-55.
[6] 朱永朝,陶金,任萌萌,熊燃,何亚琴,周瑜,卢震辉,杜勇,杨芝红. 自噬抑制肿瘤坏死因子α诱导人胎盘胎儿来源间充质干细胞发生凋亡 *[J]. 中国生物工程杂志, 2019, 39(9): 62-67.
[7] 徐燕,刘正芸,张琬棂,王盛羽,王欢. 靶向干扰TAGLN表达对HBV阳性肝癌细胞生物学行为的影响及机制初探 *[J]. 中国生物工程杂志, 2019, 39(11): 13-21.
[8] 施文雯,张蕾. 力学微环境影响间充质干细胞分化的研究现状 *[J]. 中国生物工程杂志, 2018, 38(8): 76-83.
[9] 郑妍,姚欢,杨珂. SFRP5抑制BMP9诱导人脐带间充质干细胞成骨分化的实验研究 *[J]. 中国生物工程杂志, 2018, 38(7): 7-13.
[10] 袁雅红, 赵珊珊, 王小莉, 腾智平, 李东升, 曾毅. HIV-1 Tat蛋白抑制骨髓间充质干细胞的造血支持功能[J]. 中国生物工程杂志, 2017, 37(6): 1-8.
[11] 曹俊杰, 李爱芳, 卫亚琳, 廉静, 唐敏. Notch信号参与BMP4诱导的间充质干细胞成骨分化及其机制的初步探讨[J]. 中国生物工程杂志, 2017, 37(4): 48-55.
[12] 陈文杰, 汪建样, 殷明, 殷嫦嫦. 人脐带间充质干细胞抗肿瘤机制的研究进展[J]. 中国生物工程杂志, 2017, 37(3): 78-82.
[13] 王佃亮. 细胞药物存在的问题、解决对策及发展前景——细胞药物连载之六[J]. 中国生物工程杂志, 2017, 37(2): 127-132.
[14] 赵正德, 陈振银, 张慧楠, 龚剑萍, 许少丹, 罗忠礼. 自组装短肽水凝胶支架三维培养环境对骨髓间充质干细胞生物学特性及心肌方向分化的影响[J]. 中国生物工程杂志, 2017, 37(11): 45-51.
[15] 徐丽, 吉彩霞, 刘晓骅, 喻婷婷, 罗进勇. DLX1对BMP9诱导的间充质干细胞C3H10T1/2成骨分化的影响[J]. 中国生物工程杂志, 2017, 37(10): 8-15.